Gæde, Peter http://orcid.org/0000-0002-1457-2742
Oellgaard, Jens
Kruuse, Christina
Rossing, Peter
Parving, Hans-Henrik
Pedersen, Oluf
Funding for this research was provided by:
Novo Nordisk
Article History
Received: 29 January 2019
Accepted: 3 May 2019
First Online: 1 June 2019
Duality of interest
: Since completion of data acquisition, data management and data interpretation for the Steno-2 Study’s 21.2 years follow-up, JO has been employed by Novo Nordisk Scandinavia A/B, Region Denmark. PR reports having given lectures for AstraZeneca, Bayer and Boehringer Ingelheim, has served as a consultant for AbbVie, AstraZeneca, Bayer, Eli Lilly, Boehringer Ingelheim, Astellas, Janssen and Novo Nordisk (all fees given to the Steno Diabetes Center) and has equity interest in Novo Nordisk. H-HP has equity interest in Merck and receives honoraria from AbbVie and Novartis. OP has equity interest in Novo Nordisk A/S. The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent research centre at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation. CK has equity interest in Novo Nordisk A/S. PG declares no duality of interest associated with this manuscript.